A Weapon Older Than Penicillin
Long before Alexander Fleming noticed mold killing bacteria in a petri dish in 1928, a French-Canadian microbiologist named Félix d’Hérelle was watching something stranger. In 1917, d’Hérelle observed that invisible agents in the feces of dysentery patients could dissolve bacterial colonies entirely. He called these agents bacteriophages, from the Greek for bacteria-eaters, and he was convinced they could save lives. He was right, and then largely forgotten.
Phage therapy, the practice of deploying bacteriophages to treat bacterial infections, flourished in Soviet Georgia throughout the 20th century. The Eliava Institute in Tbilisi became the world’s foremost center for phage research, producing cocktails of viruses that Soviet soldiers used to treat wound infections and gastrointestinal disease in the field. When Western medicine consolidated around antibiotics after World War II, phage therapy was dismissed as pseudoscience behind the Iron Curtain. That dismissal is now looking like one of medicine’s more costly mistakes.
It is worth pausing to appreciate just how radical d’Hérelle’s original insight was. At the time of his discovery, the germ theory of disease was still relatively new. The idea that one microscopic agent might be used to selectively hunt and destroy another was not merely novel; it was philosophically disorienting to a medical establishment that had only recently accepted that invisible organisms caused disease at all. D’Hérelle was not a cautious man. He tested phage preparations on himself before administering them to patients, and he traveled to India to treat cholera outbreaks with phage cocktails at a time when no institutional framework existed for such experiments. His methods were unorthodox by any era’s standards, but his underlying hypothesis has proven remarkably durable.
The Resistance Crisis That Changed Everything
The World Health Organization declared antimicrobial resistance one of the top ten global public health threats facing humanity. By 2019, drug-resistant infections were directly responsible for approximately 1.27 million deaths worldwide, a figure that surpasses HIV/AIDS and malaria in some annual comparisons. The pipeline of new antibiotics has slowed to a trickle, partly because pharmaceutical companies find them economically unattractive compared to drugs taken for decades rather than weeks. Developing a new antibiotic requires the same regulatory investment as any other drug, but the ideal outcome is that it is used sparingly and briefly, which makes it a poor commercial proposition in a system driven by shareholder returns.
Bacteriophages operate on a completely different biological logic. A phage is essentially a protein shell carrying a strand of genetic material. It latches onto a specific receptor on a bacterial cell wall, injects its DNA, hijacks the bacterium’s reproductive machinery, and within roughly 20 to 30 minutes causes the host cell to burst, releasing dozens of new phages that repeat the process. Crucially, phages are exquisitely specific. A phage that targets Staphylococcus aureus will ignore Escherichia coli entirely. This specificity is both the treatment’s greatest strength and its most significant logistical challenge.
That challenge is not trivial. The standard antibiotic model works precisely because broad-spectrum drugs can be deployed before a physician knows exactly which organism is causing an infection. In a septic patient deteriorating by the hour, there is no time to culture the infecting bacteria, identify the strain, and then search a library for a matching phage. This is why phage therapy, at least in its current form, is unlikely to replace antibiotics as a first-line emergency intervention. What it offers instead is a precision instrument for the growing category of patients for whom the standard toolkit has already failed, and that category is expanding faster than most people realize. The Centers for Disease Control and Prevention estimates that in the United States alone, more than 2.8 million antibiotic-resistant infections occur each year, resulting in over 35,000 deaths. Globally, projections suggest that without intervention, drug-resistant infections could claim 10 million lives annually by 2050, surpassing cancer as a cause of death.
The Landmark Cases Forcing a Reckoning
The modern revival of phage therapy is built on a small but remarkable collection of compassionate-use cases. In 2016, Tom Patterson, a professor at the University of California, San Diego, fell into a coma after contracting a pan-resistant strain of Acinetobacter baumannii while traveling in Egypt. Every antibiotic failed. His wife, epidemiologist Steffanie Strathdee, reached out to phage researchers across the United States and the Navy’s Medical Research Center. A customized phage cocktail was administered intravenously, an approach that had never been formally approved, and Patterson recovered. His case was published in Antimicrobial Agents and Chemotherapy in 2017 and became a catalyst for renewed institutional interest.
Strathdee later wrote a book about the experience, and her subsequent advocacy helped push phage therapy from the margins of academic discussion into mainstream scientific and policy conversations. What made Patterson’s case particularly significant was not merely that he survived, but that the phage cocktail used was assembled from multiple sources, refined in real time as his condition changed, and administered through a regulatory pathway that had to be improvised because no established framework existed. The entire episode illustrated both the potential and the structural unpreparedness of modern medicine to deploy this kind of treatment at scale.
Since then, the number of documented compassionate-use phage treatments has grown into the hundreds globally. A 2023 review in the journal Clinical Infectious Diseases cataloged over 100 published cases, with success rates that, while difficult to interpret without controlled trials, were striking enough to prompt regulatory agencies to adopt new frameworks. The U.S. Food and Drug Administration has allowed phage therapy under its Expanded Access program, and the agency is now working with researchers to design phage-specific clinical trial protocols that account for the fact that the therapeutic agent is itself a living, evolving entity. This last point represents a genuine regulatory novelty. Drug approval frameworks were built around chemical compounds with fixed properties. A bacteriophage can mutate. Designing a trial for a treatment that may be meaningfully different at the end of the study than it was at the beginning requires rethinking assumptions that have governed pharmaceutical regulation for decades.
Engineering the Next Generation of Phages
Natural phages have limitations beyond their specificity. Some trigger immune responses. Others carry genes that, in rare circumstances, can transfer virulence factors between bacteria. The most pressing problem is that bacteria can evolve resistance to phages just as they do to antibiotics, sometimes within days.
Synthetic biology is beginning to address these constraints in ways that would have seemed implausible a decade ago. Researchers at institutions including MIT, the University of Edinburgh, and the Pasteur Institute are engineering phages with CRISPR-based payloads that can target specific genes within bacteria, including resistance genes themselves. A phage engineered to carry a CRISPR system that cuts the gene encoding antibiotic resistance could, in principle, re-sensitize a bacterial population to drugs that previously had no effect. A 2023 study in Nature Communications demonstrated this approach in mouse models of gut infection, achieving a reduction in resistant bacterial populations by several orders of magnitude.
There is also growing interest in phage cocktails designed to stay one evolutionary step ahead of bacterial resistance. Because phages themselves evolve, researchers at the University of Exeter have experimented with allowing phages to co-evolve with target bacteria in controlled laboratory conditions before administration, essentially training the virus to overcome resistance mechanisms before it ever enters a patient. This approach, sometimes called experimental evolution, draws on principles from evolutionary biology that have rarely been applied in a clinical context. It is a striking example of how the resistance crisis is forcing medicine to think on timescales and in terms of dynamics that conventional pharmacology was never designed to accommodate.
One additional frontier involves the use of phage-derived enzymes called lysins, which can be extracted from phages and deployed independently. Lysins attack bacterial cell walls directly and can kill bacteria in seconds, including strains resistant to every known antibiotic. Because lysins are proteins rather than living viruses, they are easier to standardize and manufacture, and they sidestep some of the regulatory complexity that makes whole-phage therapy difficult to scale. Several lysin-based drugs are currently in clinical trials in the United States and Europe, representing a parallel track of development that may reach patients sooner than phage therapy itself.
What Soviet Science Got Right
The Eliava Institute in Tbilisi, which survived the collapse of the Soviet Union in severe underfunding, has experienced something of a renaissance. International collaborations with Belgian, French, and American research groups have brought new equipment and funding. The institute maintains one of the largest bacteriophage libraries in the world, a collection of viral strains gathered over more than 80 years that Western researchers are now mining for candidates against resistant pathogens.
There is an irony embedded in this history that the scientific community is beginning to openly acknowledge. The Cold War’s ideological divisions led Western medicine to dismiss an entire field of research because of its geographic and political associations. The Eliava Institute’s work was not pseudoscience. It was underpublished, underfunded, and conducted in a language and within a system that Western journals rarely engaged with. The consequence was a 50-year delay in developing a therapy that might now be essential to keeping modern surgery, cancer chemotherapy, and organ transplantation viable, all of which depend on the ability to control bacterial infection.
This history carries a lesson that extends beyond bacteriophages. Science conducted outside the dominant institutional networks of any given era is routinely undervalued, not because it lacks merit, but because the mechanisms for evaluating merit are themselves shaped by geography, language, funding structures, and political circumstance. The dismissal of Soviet phage research is one of the cleaner examples of this dynamic, but it is unlikely to be the last. As the global center of scientific production continues to shift, with major research output now coming from China, India, Brazil, and across Africa, the question of how Western institutions engage with work produced outside their traditional orbit remains as consequential as it was during the Cold War.
Phage therapy will not replace antibiotics. Its specificity makes it impractical as a first-line treatment in emergency settings where the infecting organism has not yet been identified. But as a precision tool for infections that have exhausted every other option, the bacteriophage may be among the most consequential medical rediscoveries of the 21st century. What began as an observation about dissolving bacterial colonies in 1917, was sidelined by ideology, and survived in a single underfunded institute in the Caucasus, is now at the center of one of the most urgent problems in global medicine. The story of phage therapy is, among other things, a reminder that the archive of abandoned science deserves more attention than it typically receives.